Table 3.
The construct validity of 5-level EuroQoL-5 dimension version.
| Constructs | EQ-5D-5La index (English value set) | EQ-5D-5L index (French 3L-5L crosswalk) | EuroQol visual analog scale | |||||||||||||||||||
| Mean (SD) | Effect size (95% CI) | Mean (SD) | Effect size (95% CI) | Mean (SD) | Effect size (95% CI) | |||||||||||||||||
| Other chronic conditions | ||||||||||||||||||||||
|
|
0 chronic conditions | 0.91 (0.11) | Reference | 0.86 (0.14) | Reference | 78.91 (14.85) | Reference | |||||||||||||||
|
|
1 chronic condition | 0.89 (0.10) | 0.14 (–0.21 to 0.48) | 0.85 (0.15) | 0.05 (–0.26 to 0.36) | 79.08 (13.23) | 0.06 (–0.25 to 0.37) | |||||||||||||||
|
|
≥2 chronic conditions | 0.82 (0.13) | 0.62 (0.18 to 1.06) | 0.75 (0.20) | 0.60 (0.18 to 1.02) | 72.94 (17.22) | 0.37 (–0.04 to 0.79) | |||||||||||||||
|
|
P value | .002b,c | —d | .003b,c | — | .12 | — | |||||||||||||||
| Number of SABAe canisters prescribed (last year) | ||||||||||||||||||||||
|
|
0 canisters | 0.89 (0.11) | Reference | 0.85 (0.15) | Reference | 78.84 (12.90) | Reference | |||||||||||||||
|
|
1-4 canisters | 0.87 (0.14) | 0.11 (–0.18 to 0.39) | 0.82 (0.19) | 0.19 (–0.07 to 0.45) | 76.64 (17.93) | 0.21 (–0.06 to 0.47) | |||||||||||||||
|
|
5 or more canisters | 0.81 (0.17) | 0.58 (0.14 to 1.01) | 0.76 (0.22) | 0.46 (0.05 to 0.86) | 72.00 (24.52) | 0.47 (0.07 to 0.88) | |||||||||||||||
|
|
P value | .02b | — | .03b | — | .15 | — | |||||||||||||||
| Frequency of SABA use reported by patient (last 4 weeks) | ||||||||||||||||||||||
|
|
Less than once a week | 0.82 (0.19) | Reference | 0.74 (0.23) | Reference | 71.45 (19.85) | Reference | |||||||||||||||
|
|
Once or twice a week | 0.87 (0.15) | 0.17 (–0.11 to 0.44) | 0.81 (0.21) | 0.29 (0.03 to 0.55) | 78.08 (12.92) | 0.07 (–0.19 to 0.32) | |||||||||||||||
|
|
Almost every day or every day | 0.89 (0.12) | 0.50 (0.11 to 0.89) | 0.85 (0.16) | 0.50 (0.15 to 0.84) | 78.61 (16.26) | 0.37 (0.03 to 0.71) | |||||||||||||||
|
|
P value | .03b | — | .01b | — | .07 | — | |||||||||||||||
| Asthma Control Questionnaire | ||||||||||||||||||||||
|
|
Well-controlled (<0.75) | 0.93 (0.10) | Reference | 0.91 (0.13) | Reference | 81.65 (13.80) | Reference | |||||||||||||||
|
|
Intermediate (0.75-1.5) | 0.87 (0.11) | 0.44 (0.15 to 0.72) | 0.81 (0.15) | 0.47 (0.22 to 0.73) | 79.18 (11.92) | 0.15 (–0.11 to 0.40) | |||||||||||||||
|
|
Not well-controlled (>1.5) | 0.78 (0.19) | 1.06 (0.74 to 1.38) | 0.69 (0.24) | 1.04 (0.75 to 1.32) | 68.39 (20.23) | 0.79 (0.51 to 1.08) | |||||||||||||||
|
|
P value | <.001b,c,f | — | <.001b,c,f | — | <.001b,c | — | |||||||||||||||
aEuroQol-5 Dimensions-5 Levels.
bFirst category (reference) versus third category.
cSecond category versus third category.
dP value not necessary as the CI was calculated.
eSABA: short-acting beta-agonist.
fFirst category (reference) versus second category.